Phase I-II study of intratumor immunotherapy with BCG cell wall skeleton plus P3

S. P. Richman, J. U. Gutterman, E. M. Hersh, E. E. Ribi

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

A vaccine composed of BCG cell wall skeleton (CWS) and a trehalose dimycolate called P3, attached to microdroplets of mineral oil, was evaluated for activity and toxicity when injected into tumor nodules. A total of 99 nodules in 23 patients with metastatic melanoma and carcinoma of the breast were treated overa dose range of 150 μg, 300 μg, and 600 μg cell wall skeleton plus P3 per cm of nodule diameter. At least one injected nodule resolved in 11 of the 23 patients (48%), and 34% of all injected nodules resolved. Response correlated with nodule size of 1 cm or less, cutaneous location, and immunocompetence measured by PPD and recall skin testing. Toxicity became manifest in ulceration (61% of patients), fever (52%), and pain (26%).

Original languageEnglish (US)
Pages (from-to)41-44
Number of pages4
JournalCancer Immunology Immunotherapy
Volume5
Issue number1
DOIs
StatePublished - Nov 1978

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I-II study of intratumor immunotherapy with BCG cell wall skeleton plus P<sub>3</sub>'. Together they form a unique fingerprint.

  • Cite this